Nan Zhang

Dr. Nan Zhang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
NZNan Zhang
Nan Zhang
MGMarc L Gordon
Marc L Gordon
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer’s disease (AD) in China. However, there are few studies focusing on the efficacy and safety of donepezil in Chinese patients. In this review, we discuss 1) the efficacy of donepezil and its comparison with other AChEIs or memantine, 2) the therapeutic responses to donepezil and its influencing factors, and 3) the safety and tolerability of donepezil in Chinese patients with different stages of AD and amnestic mild cognitive impairment, and further compare the similarities and differences of the results between Chinese studies and previous Western studies that predominantly enrolled Caucasian subjects. We include Chinese clinical trials and other well-designed studies investigating donepezil or using donepezil as a positive control, in which the efficacy and/or safety of donepezil have been analyzed. Based on these studies, donepezil has been shown to be effective and safe in Chinese AD patients and may impact AD biomarkers, such as hippocampal atrophy, Aβ, and tau. In addition, the therapeutic response to donepezil may be influenced by apolipoprotein E or cytochrome P450 2D6 polymorphism.

13 August 2020 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
DGDongmei Gu
Dongmei Gu
FLFang Liu
Fang Liu
MMMeng Meng
Meng Meng
LZLiling Zhang
Liling Zhang
MGMarc L. Gordon
Marc L. Gordon
NZNan Zhang
Nan Zhang
Objective: This study aimed to investigate plasma neuronally derived extracellular vesicle (NDEV) levels of core pathological markers [amyloid‐β (Aβ) and phosphorylated tau] and inflammatory biomarkers, including interleukin 6 (IL‐6) and matrix metalloproteinase‐9 (MMP‐9) in patients with Alzheimer’s disease (AD).Methods: Thirty‐one patients with AD and 15 cognitively normal controls (NCs) were recruited. The diagnosis of AD was supported by fluorodeoxyglucose and Pittsburgh Compound‐B PET scans. Plasma extracellular vesicles were extracted, precipitated, and enriched for neuronal source by anti‐L1CAM antibody absorption. Levels of Aβ42, P‐T181‐tau, P‐S396‐tau, IL‐6, and MMP‐9 in plasma NDEVs were quantified by enzyme‐linked immunosorbent assay (ELISA).Results: Aβ42, P‐T181‐tau, and MMP‐9 levels in plasma NDEVs were significantly higher in patients with AD than NCs. However, P‐S396‐tau and IL‐6 levels in plasma NDEVs did not differ between AD patients and NCs. Moreover, there was no correlation between any of these biomarker levels and cognitive function as measured with Mini‐Mental State Examination in patients with AD.Conclusions: These findings provide further support that levels of core pathological markers, including Aβ42 and P‐T181‐tau, are elevated in plasma NDEVs of patients with AD. Furthermore, MMP‐9 might play an important role in the pathogenesis of AD, and is a promising inflammatory biomarker for AD.

3 December 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
GXGebeili Xing
Gebeili Xing
TZTianman Zhao
Tianman Zhao
XZXiyue Zhang
Xiyue Zhang
HLHe Li
He Li
XLXiuping Li
Xiuping Li
WJWei Jiang
Wei Jiang
Background: Intracerebral hemorrhage (ICH) is a fatal subtype of stroke that lacks effective therapy. Blood-brain barrier (BBB) damage is a hallmark of ICH-induced brain injury that leads to edema formation, leukocytes infiltration, influx of blood components into the perihematomal (PHE) region, and eventually brain injury. Astrocytes are essential for the formation and maintenance of the BBB by providing secreted molecules that contribute to the association between these cells. Sonic hedgehog (SHH) derived from astrocytes promotes the maturity and integrity of the BBB by upregulating tight junctions (TJs) in brain capillary endothelial cells (ECs). However, the effect of SHH on BBB in ICH has not been investigated.Methods: Cyclopamine (CYC) is a potent, selective inhibitor that specifically blocks the SHH signaling pathway. Here, we used pharmacological inhibitions (CYC and its derivatives) to determine a critical role of the SHH signaling pathway in promoting BBB integrity after ICH by mechanisms of regulating the TJ proteins in vivo and in vitro.Results: The expression of astrocytic SHH was upregulated in mouse brains after ICH. Compared with the vehicle-treated group, inhibition of the SHH signaling pathway with CYC and its derivatives treatments aggravated neurological function deficits, brain edema, hematoma volume, and BBB impairment by downregulating TJs in ECs through the SHH-Gli-1 axis in vivo and in vitro.Conclusions: SHH signaling pathway at the level of the BBB provides a barrier-promoting effect, suggesting that the SHH signaling pathway may function as a potential therapeutic target for restoring BBB function in ICH.

4 June 2020 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
NZNan Zhang
Nan Zhang
DGDongmei Gu
Dongmei Gu
MMMeng Meng
Meng Meng
MGMarc L. Gordon
Marc L. Gordon
Background: Recently, TDP-43 has been recognized as a common proteinopathy in the “oldest old” and a neuropathological comorbidity in patients with Alzheimer’s disease (AD). However, since it has a low concentration in cerebrospinal fluid, the presence of TDP-43 in AD is rarely investigated in vivo. Methods: Twenty-four patients with amyloid PET confirmed AD and 15 healthy controls (HCs) were included in this study. TDP-43 level in plasma neuronal-derived exosomes (NDEs) was measured by enzyme-linked immunosorbent assay. Results: TDP-43 level was elevated in patients with AD compared with HCs (median 1.08 ng/ml, IQR 0.72–1.37 ng/ml vs. median 0.66 ng/ml, IQR 0.48–0.76 ng/ml, P = 0.002). There was no correlation between TDP-43 level and cognitive function, neuropsychiatric symptoms or APOE genotype in patients with AD. Conclusion: This study demonstrated increased TDP-43 accumulation in AD patients by examining plasma NDEs, which may provide a window into the effects of TDP-43 on AD progression.

29 August 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
NZNan Zhang
Nan Zhang
LZLiling Zhang
Liling Zhang
YLYan Li
Yan Li
MGMarc L. Gordon
Marc L. Gordon
LCLi Cai
Li Cai
YCYan Cheng
Yan Cheng
Background: Expression of neuronal thread protein (NTP), which is considered to be related to neuritic sprouting and neuronal death, may be elevated in brain tissue, cerebrospinal fluid, and even urine in patients with Alzheimer’s disease (AD). Objec

8 February 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PCPing Che
Ping Che
JZJuan Zhang
Juan Zhang
MYMingqian Yu
Mingqian Yu
PTPing Tang
Ping Tang
YWYanhui Wang
Yanhui Wang
NZNan Zhang
Nan Zhang
Aims: DL‐3‐n‐butylphthalide (NBP) exerts beneficial effects on global cognitive functions, but the underlying molecular mechanisms are still poorly understood. The present study aimed to investigate whether NBP mediates synaptic plasticity and blood–brain barrier (BBB) function, which play a pivotal role in the pathogenesis of vascular dementia (VaD), in a mouse model of bilateral common carotid artery stenosis (BCAS).Methods: NBP was administered to model mice at a dose of 80 mg/kg by gavage for 28 days after surgery. Cognitive function was evaluated by behavioral tests, and hippocampal synaptic plasticity was evaluated by in vivo electrophysiological recording. Cerebral blood flow (CBF), hippocampal volume, and white matter integrity were measured with laser speckle imaging (LSI) and MRI. In addition, BBB leakage and the expression of proteins related to the Akt/ERK and HIF‐1α/MMP signaling pathways were assessed by biochemical assays.Results: NBP treatment alleviated cognitive impairment, hippocampal atrophy, and synaptic plasticity impairment induced by BCAS. In addition, NBP treatment increased CBF, promoted white matter integrity, and decreased BBB leakage. Regarding the molecular mechanisms, in mice with BCAS, NBP may activate the Akt/ERK signaling pathway, which upregulates the expression of synapse‐associated proteins, and it may also inhibit the HIF‐1α/MMP signaling pathway, thereby increasing the expression of tight junction (TJ) proteins.Conclusion: In conclusion, our results demonstrated the therapeutic effects of NBP in improving cognitive function via a wide range of targets in mice subjected to BCAS.